When does Kuros report earnings and why does it matter for KURN.SW stock?

Kuros reports on 10 Mar 2026. The print matters because guidance and sales updates for MagnetOs and clinical programs will shape near-term revenue visibility and affect KURN.SW stock’s premium valuation.

What is Meyka AI’s price forecast for KURN.SW stock and the implied upside?

Meyka AI's yearly forecast for KURN.SW stock is **CHF34.56**, implying an **18.19%** upside versus today’s **CHF29.24**. Forecasts are model-based and not guarantees.

What are the main valuation risks for KURN.SW stock?

Valuation risks include high multiples (P/S **9.71**, P/B **13.80**), negative EPS, and reliance on successful commercialization and trial outcomes. Any revenue miss would increase downside pressure on KURN.SW stock.

How does sector performance influence KURN.SW stock near earnings?

Swiss Healthcare averages a PE of **30.01** and PB **4.85**. Kuros’s premium metrics mean sector headwinds or risk-off moves could amplify downside for KURN.SW stock if company-specific results disappoint.

CH Stocks

KURN.SW Kuros Biosciences up 10.84% to CHF29.24: earnings today 10 Mar 2026, watch guidance

ByDanny Kontos March 10, 2026March 10, 2026

KURN.SW stock jumps 10.84% intraday to CHF29.24 as Kuros Biosciences AG (SIX) heads into its earnings announcement on 10 Mar 2026. The move comes on volume of 560,432.00 shares and follows a gap open at CHF27.70. Investors will watch revenue trends, the company’s EPS of -0.12, and management comments on orthobiologics sales. This earnings spotlight frames today’s price action against Kuros’s pipeline progress and sector comparatives in Swiss healthcare.